66 results about "Central nerve system" patented technology

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

The present disclosure relates to compounds according to Formula I or a pharmaceutically acceptable salt and / or solvate thereof, wherein X 1 is H, F, or CI; R 1 is H, alkyl, or cycloalkyl; R 2 is H, alkyl, or cycloalkyl; R 3 is H, halo, alkyl, cycloalkyl, heterocyclyl, heteroaryl, or N(R 4 )(R 5 ); and one of R 4 and R 5 is H, alkyl, cycloalkyl, heterocyclyl, or heteroaryl, and the remaining one of R 1 and R 2 is H or alkyl, or R 4 and R 5 together with the nitrogen atom to which they are bound are heterocyclyl or heteroaryl. Furthermore, the present disclosure demonstrates that the compounds of the present disclosure penetrate the central nervous system, thereby allowing for the treatment of central nervous system cancers.

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

The application discloses a polypeptide GRN-E and application thereof in preparation of a medicine or preparation for perimenopausal emotional disorder. It is found for the first time that a GRN-E fragment (a C-terminal domain of PGRN, an amino acid sequence is SEQ ID NO. 1 in a sequence listing) can pass through a blood-brain barrier and has a unique effect in relieving perimenopausal anxiety and depression. As a key functional fragment, the GRN-E has a more concentrated effect on a central nervous system and can effectively avoid off-target effects of a full-length protein. The polypeptide GRN-E of the application can be applied to preparation of a medicine or preparation for perimenopausal emotional disorder as an innovative treatment target and a novel biological preparation and has a high clinical conversion value.

This application provides antisense nucleic acid compounds that reduce the levels of certain nutrients in neurons of the central nervous system. UBE3A This application also provides compositions comprising antisense nucleic acid compounds and their application in the prevention or treatment of overdose in subjects. UBE3A Use in methods related to mRNA and / or UBE3A peptide levels.

This invention discloses a dosage analysis method for anesthetic drugs during surgery in patients with hypertension, hyperlipidemia, and hyperglycemia. This method integrates multi-source heterogeneous health data from the patient over the past five years to construct a personalized, structured health record. During anesthesia induction, based on the patient's individualized pharmacokinetic model and assessed drug interaction risks, it calculates and recommends precisely adjusted induction doses. During anesthesia maintenance, it innovatively decodes specific EEG signals to establish a dynamic mapping relationship between neurophysiological characteristics and pharmacokinetics. Based on EEG characteristics reflecting drug sensitivity and pain perception, it automatically and in real-time adjusts the predicted concentration of the target drug, achieving closed-loop precise control based on direct feedback from the central nervous system. The system automatically identifies all medications used by the patient, generates a drug interaction risk assessment report using a massive knowledge base, and dynamically updates the risk level and sends warnings during surgery based on real-time vital signs.

This document discloses MTS peptides or targeting peptides. MTS peptides comprising the amino acid sequence of any one of SEQ ID NO: 1-12 are disclosed. Compositions comprising peptides, wherein the peptides comprise a first MTS peptide conjugated to a cargo, are disclosed. Methods of using MTS peptides are also disclosed. For example, a method of transporting cargo to a CNS is disclosed, the method comprising administering one or more of the disclosed compositions to a subject in need, wherein the cargo-conjugated peptide enters the CNS.

The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.

The application relates to an artificial visual nervous system based on a bimodal neural device, comprising a bimodal visual information calculation array composed of a physical convolution kernel array and a synapse calculation array, the physical convolution kernel array is used for receiving an ambient light signal and converting into an electrical signal output, the synapse calculation array is used for receiving the electrical signal and converting into a visual signal, and the physical convolution kernel array and the synapse calculation array are both composed of a plurality of bimodal transistors. The application has excellent bimodal collaborative calculation capability, the receptive field mechanism (excitatory / inhibitory response) of a retinal bipolar cell is simulated through the physical convolution kernel array, image feature extraction and preprocessing are realized, the synaptic plasticity (LTP / LTD mechanism) of a central nervous system is simulated in combination with the synapse calculation array, high-level calculation of the visual signal is completed, and a complete visual nerve bionic system is formed by virtue of an array composed of single devices.

The application provides a molecular diagnosis method combining a multi-enzyme isothermal rapid amplification technology (MIRA) and a CRISPR-Cas12a nucleic acid detection technology, and particularly relates to application thereof in rapid, sensitive and specific detection of common pathogenic bacteria of a central nervous system (CNS). The application combines the multi-enzyme isothermal rapid amplification technology and the CRISPR-Cas12a nucleic acid detection system, realizes rapid, sensitive and specific detection of nucleic acids of common pathogenic bacteria of the CNS under a constant temperature condition, and thus provides a new technical means for early diagnosis of the CNS infection.

The present application provides a kind of nutritional composition in the application of the product for improving learning, memory and cognitive ability.The nutritional composition includes animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose.Animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose can synergistically enhance the memory retention ability of the body, reduce the degree of learning and memory errors, and up-regulate the expression of oligodendrocyte transcription factor 2 coding gene, myelin basic protein coding gene and brain-derived neurotrophic factor coding gene, realize the double regulation of myelin formation and neurotrophic in hippocampus region of brain, synergistically improve the neural plasticity of central nervous system through gut-brain axis pathway, and then double improve the learning, memory and cognitive function of the body from the behavior and molecular level.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

This disclosure relates to 1,4-oxazolidinyl heptane and 1,4-thioazolidinyl heptane derivatives, and their use in treating conditions and diseases associated with the lanodid receptor (RyR), which regulates calcium channel signaling in cells. This disclosure also discloses pharmaceutical compositions comprising these compounds and their use in treating diseases and conditions associated with RyR dysfunction, particularly cardiovascular, musculoskeletal, and central nervous system (CNS) disorders.

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

Enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of eye or central nervous system (CNS) disorders, wherein the rAAV comprises one or more amino acid substitutions that interact with the heparan sulfate proteoglycan. The invention provides methods for enhancing retinal cell transduction and methods for treating eye diseases with enhanced compositions of rAAV particles. Furthermore, enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of CNS disorders. The invention provides methods for delivering the rAAV to the CNS, methods for treating CNS disorders with enhanced compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

The present disclosure relates to compositions, formulations, and associated methods for treating neurodegenerative diseases, wherein the compositions include an alpha-1 adrenergic agonist, such as midodrine, and an alpha-2A adrenergic agonist, such as dexmedetomidine. Upon administering to a human subject, the alpha-2A adrenergic agonist crosses the subject's blood-brain barrier thereby acting upon the subject's central nervous system, whereas the alpha-1 adrenergic agonist does not cross the subject's blood-brain barrier. The alpha-1 adrenergic agonist minimizes or eliminates the systemic vascular effects induced by the alpha-2A adrenergic agonist that causes the negative cerebral autoregulatory response, thereby enabling the alpha-2A adrenergic agonist to increase glymphatic flow in the subject's brain.

A recombinant adeno-associated virus (rAAV) useful for treating type II glycogen storage disease (Pompe) disease is provided. The rAAV comprises an AAV capsid which targets cells of at least one of muscle, heart, kidney, and the central nervous system and which has packaged therein a vector genome comprising a nucleic acid sequence encoding a human acid-α-glucosidase hGAA780I protein or fusion protein under the control of regulatory sequences which direct its expression. Also provided are methods of making and using this rAAV.

The invention concerns nanovesicles of nanostructured myelin and uses thereof in the treatment of demyelinating and neurodegenerative diseases of the central (CNS) and peripheral (PNS) nervous system. Under another aspect, processes for the preparation of myelin nanovesicles having particular characteristics that make them suitable for recovery of the myelin sheath, where it is compromised, as a drug delivery system for CNS or PNS, and for immunotolerance, are described.

The invention relates to compound essential oil with effects of dredging collaterals and sterilizing. The compound essential oil is prepared by mixing the following substances: essential oil extracted by squeezing Chinese prickly ash, essential oil extracted by distilling folium eucalypti, a cypress root distillation extract, a sesame squeezing extract, cinnamomum camphora leaf distillation extract borneol and forest musk secretion. In the composition, the essence oil extracted by squeezing the Chinese prickly ash has various effects of resisting inflammation, easing pain, inhibiting bacteria, killing insects, relieving itching, resisting tumors, resisting oxidation, promoting transdermal absorption, improving central nervous system disorders and the like. Essential oil distilled and extracted from eucalyptus leaves has the effects of resisting bacteria, diminishing inflammation, relieving respiratory tract symptoms, promoting wound healing, relieving muscular pain, expelling parasites and the like. The cypress root distillation extract has antibacterial and anti-inflammatory effects. And the sesame extract has the effects of resisting oxidation, resisting aging and whitening. The musk has the effects of inducing resuscitation, activating blood to promote menstruation and relieving swelling and pain. The cinnamomum camphora leaf distillation extract has a remarkable anti-inflammatory effect. The compositions cooperate with one another, and the action effect is obvious.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

The present invention provides a central nervous system targeted pharmaceutical composition that can be used to treat various forms of brain damage, wherein an integrin antibody is attached to a transmembrane protein of an exosome through genetic engineering, and said exosome is used as a carrier to encapsulate a therapeutic drug.

This invention relates to novel neurotropic adeno-associated virus (AAV) capsid variants. In particular, the invention relates to novel AAV capsid variants that efficiently transduce cells in the central nervous system (CNS) upon systemic administration, while exhibiting reduced transduction to peripheral organs. The invention further relates to a method for identifying AAV capsid variants having one or more desired properties, such as a combination of CNS targeting and peripheral organ detargeting.

The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.

This invention relates to compositions and methods for improving recovery after traumatic or ischemic central nervous system injury, including the administration of compositions comprising cyclopropenzyme (AOS) or its functionally equivalent variants or derivatives.

The present disclosure relates to methods of control, treatment and / or prevention of a neurological disease or disorder in animals, optionally livestock, comprising administering a therapeutically effective amount of a fluoroquinolone compound, optionally pradofloxacin, or a pharmaceutically acceptable salt, solvate, hydrate or hydrate of salt thereof, wherein the neurological disease or disorder is caused by a bacterial infection in the central nervous system. The present disclosure further provides a method of control, treatment and / or prevention of a bacterial infection in the central nervous system in animals, optionally livestock, comprising administering a therapeutically effective amount of a fluoroquinolone compound, optionally pradofloxacin, or a pharmaceutically acceptable salt, solvate, hydrate or hydrate of salt thereof.

This application relates to the fields of biomedical engineering and neuromodulation, disclosing the application of ultrashortwave in the fabrication of devices for modulating brain neural activity. The modulation of brain neural activity is achieved through the non-thermal effects of ultrashortwave, which refers to ultrashortwave with a frequency of 27.12MHz ± 0.6%, a wavelength of 11.06 nm, and a power of 1.6 ± 0.72 W. This application breaks through the traditional technical prejudice that high-frequency electric fields are unsuitable for the central nervous system, proving that non-thermal ultrashortwave can be safely used for brain neural modulation, opening up a completely new technical direction for neural modulation. With "ultrashortwave + application scenario" as its core protection element, it provides fundamental patent support for research on the treatment of various central nervous system diseases such as Parkinson's disease, stroke, depression, and Alzheimer's disease, possessing extremely high core patent value and broad clinical translation prospects.

Magnetic resonance imaging (MRI) is used to image the slow flow of cerebrospinal fluid (CSF) in subarachnoid and perivascular spaces, amongst other regions of the brain and central nervous system. The slow CSF flow imaging can be provided by using low velocity’ encoding (VENC) and an efficient data acquisition. Tailored image processing can be used to further improve the accuracy, specificity, and visualization of CSF flow dynamics.

The present invention is directed to novel compounds, SIR agonist compounds of Formula I, compositions and methods for the prevention and / or treatment of inflammation in various tissues and organs. Preferably, embodiments of the present invention relate to the use of said compounds in the prevention and / or treatment of excessive production of pro-inflammatory cytokines in a medical or disease condition. The prior art compound crosses the blood-brain barrier (BBB) and acts on the central nervous system (CNS). The CNS activity is not a desired effect in anti-inflammatory treatment outside the brain. Thus, we have developed novel compounds having anti-inflammatory activity with no, or minimal CNS activity.